StemCell Institute

StemCell Institute ROE

The Return on Equity (ROE) of StemCell Institute (7096.T) as of Nov 1, 2026 is 5.81 %. In the previous year, Return on Equity (ROE) was 14.68 % — a change of -60.40% (lower).

ROE

5.81 %

YoY

-60.40%

Last updated:

In 2026, StemCell Institute's return on equity (ROE) was 5.81 %, a -60.40% increase from the 14.68 % ROE in the previous year.

The StemCell Institute ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2019
14.54 JPY
Jan 1, 2020
21.99 JPY
Jan 1, 2021
4.72 JPY
Jan 1, 2022
6.36 JPY
Jan 1, 2023
8.62 JPY
Jan 1, 2024
11.55 JPY
Jan 1, 2025
14.68 JPY
Jan 1, 2026
5.81 JPY
The StemCell Institute ROE history
YEARROEYoY
5.81 %-60.40%
14.68 %+27.12%
11.55 %+34.06%
8.62 %+35.55%
6.36 %+34.74%
4.72 %-78.55%
21.99 %+51.22%
14.54 %+75.51%
8.28 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

StemCell Institute Stock analysis

What does StemCell Institute do? StemCell Institute KK operates a cell bank business segment focused on storing umbilical cord blood and cord tissue. The company collects umbilical cord blood from pregnant women through contracts with domestic cooperative hospitals, including university hospitals and obstetric clinics, then processes and stores the stem cells at its centers in Minato-ku, Tokyo, and Midori-ku, Yokohama. The firm generates revenue by charging customers for the separation, storage, and long-term preservation of stem cells, targeting expectant parents seeking future medical options. Its primary customer segment consists of pregnant women who sign storage contracts before childbirth. The company develops regenerative medicine products and new treatment methods, expanding its offerings beyond basic storage. It also invests in childbirth and childcare-related business areas, aligning with its core cell bank operations. StemCell Institute KK's revenue streams include fees for umbilical cord blood banking services and potential future sales of regenerative medicine products developed through its research and development efforts. StemCell Institute KK's business model centers on long-term storage contracts with customers, leveraging its cell processing and storage infrastructure. The firm's revenue is derived from upfront and recurring fees associated with the collection, processing, and preservation of stem cells from umbilical cord blood, with no mention of additional revenue sources such as partnerships or external investments in the provided description. StemCell Institute is one of the most popular companies on Eulerpool.

ROE Details

Decoding StemCell Institute's Return on Equity (ROE)

StemCell Institute's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing StemCell Institute's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

StemCell Institute's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in StemCell Institute’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about StemCell Institute stock

Return on Equity (ROE) of StemCell Institute is 5.81 % in 2026.

Return on Equity (ROE) of StemCell Institute changed from 14.68 % to 5.81 %, representing a -60.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) StemCell Institute since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s StemCell Institute with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — StemCell Institute

All Key Metrics — StemCell Institute